Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus

被引:5
作者
Pandya, Bhavik J. [1 ]
Bron, Morgan
McCall, Therese
Yu, Andrew P. [2 ]
Chen, Kristina S. [2 ]
Mattson, Miles E. [2 ]
Wu, Eric Q. [2 ]
机构
[1] Takeda Pharmaceut Int Inc, Global Hlth Econ & Outcomes Res, Deerfield, IL 60015 USA
[2] Anal Grp Inc, Boston, MA USA
关键词
Combination therapy; Diabetes mellitus; Metformin; Pioglitazone; DOUBLE-BLIND; EFFICACY; TOLERABILITY; MONOTHERAPY; SULFONYLUREA; VILDAGLIPTIN;
D O I
10.1185/03007995.2010.536755
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To compare glycemic goal achievement (HbA(1c) < 7%) in type 2 diabetes patients receiving initial metformin plus pioglitazone combination therapy and initial metformin monotherapy augmented with pioglitazone in a cohort follow-up study. Adult patients were identified from the Ingenix Impact database (01/01/99-03/31/07). Qualified patients had a baseline HbA(1c) epsilon 7%; a second laboratory value within 9 months; no other anti-diabetic prescriptions 6 months before or 30 days after treatment initiation; and continuous enrollment during baseline. The index date was the date on which the second medication was initiated. Goal achievement was compared independently at 6, 12 and 18 months using a chi-square test. Logistic regression was used to control for baseline differences. Last observation carried forward was used to impute missing HbA(1c) values. Sub-group analysis was conducted on patients with baseline HbA(1c) values between 7% and 9%, and > 9%. The proportion of patients achieving glycemic goal at each specified time point. A total of 179 patients received initial combination therapy and 347 patients received sequential therapy. A greater proportion of initial combination patients achieved the glycemic goal compared to sequential patients at months 6, 12 and 18 (66.5 vs. 49.6%; 65.9 vs. 48.1%; 65.9 vs. 48.4%, respectively; p < 0.001 for all). Logistic regression confirmed these findings (odds ratios [OR]: 3.18-3.31). Sub-group analysis showed a more pronounced advantage for aggressive initial combination treatment among patients with HbA(1c) > 9% (OR: 5.39-6.04) than among patients with HbA(1c) between 7% and 9% (OR: 2.28-2.79). Initial combination therapy patients are more likely to achieve glycemic control than sequential therapy patients, especially for patients with baseline HbA(1c) > 9%. This study is limited by the relatively small sample size and the frequency of HbA(1c) reporting. Future research could examine goal achievement using a larger sample and more complete laboratory data to confirm these findings.
引用
收藏
页码:189 / 195
页数:7
相关论文
共 23 条
[1]  
*AM COLL END, 2006, ENDOCR PRACT, V12, P6
[2]   Standards of Medical Care in Diabetes-2009 [J].
不详 .
DIABETES CARE, 2009, 32 :S13-S61
[3]  
[Anonymous], 2007, NATL DIABETES FACT S
[4]   Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study [J].
Bolli, G. ;
Dotta, F. ;
Rochotte, E. ;
Cohen, S. E. .
DIABETES OBESITY & METABOLISM, 2008, 10 (01) :82-90
[5]   Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes [J].
Charbonnel, B ;
Schernthaner, G ;
Brunetti, P ;
Matthews, DR ;
Urquhart, R ;
Tan, MH ;
Hanefeld, M .
DIABETOLOGIA, 2005, 48 (06) :1093-1104
[6]   Piogfitazone/metformin [J].
Deeks, Emma D. ;
Scott, Lesley J. .
DRUGS, 2006, 66 (14) :1863-1877
[7]   ADAPTING A CLINICAL COMORBIDITY INDEX FOR USE WITH ICD-9-CM ADMINISTRATIVE DATABASES [J].
DEYO, RA ;
CHERKIN, DC ;
CIOL, MA .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (06) :613-619
[8]   Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy [J].
Fonseca, Vivian A. ;
Rosenstock, Julo ;
Wang, Antonia C. ;
Truitt, Kennetit E. ;
Jones, Michael R. .
DIABETES CARE, 2008, 31 (08) :1479-1484
[9]   The cost to health plans of poor glycemic control [J].
Gilmer, TP ;
OConnor, PJ ;
Manning, WG ;
Rush, WA .
DIABETES CARE, 1997, 20 (12) :1847-1853
[10]   Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes [J].
Goldstein, Barry J. ;
Feinglos, Mark N. ;
Lunceford, Jared K. ;
Johnson, Jeremy ;
Williams-Herman, Debora E. .
DIABETES CARE, 2007, 30 (08) :1979-1987